新型胰岛素、生物类似药与胰岛素治疗 - Suppr

Suppr

超能文献

New Insulins, Biosimilars, and Insulin Therapy.

作者信息

Danne Thomas, Heinemann Lutz, Bolinder Jan

机构信息

1 Diabetes-Zentrum für Kinder and Jugendliche, Kinder- und Jugendkrankenhaus AUF DER BULT , Hannover, Germany .

2 Science & Co GmbH , Düsseldorf, Germany .

出版信息

Diabetes Technol Ther. 2017 Feb;19(S1):S42-S58. doi: 10.1089/dia.2017.2505.

DOI:10.1089/dia.2017.2505

PMID:28192016

Abstract

摘要

相似文献

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2017 Feb;19(S1):S42-S58. doi: 10.1089/dia.2017.2505.

Role of Devices in Insulin Delivery.

Diabetes Technol Ther. 2017 Feb;19(2):76-78. doi: 10.1089/dia.2017.0011.

Novel and Emerging Insulin Preparations for Type 2 Diabetes.

Can J Diabetes. 2015 Dec;39 Suppl 5:S160-6. doi: 10.1016/j.jcjd.2015.09.082.

New Medications for the Treatment of Diabetes.

Diabetes Technol Ther. 2017 Feb;19(S1):S128-S140. doi: 10.1089/dia.2017.2512.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2018 Feb;20(S1):S55-S70. doi: 10.1089/dia.2018.2505.

Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.

Can J Diabetes. 2015 Dec;39 Suppl 5:S176-82. doi: 10.1016/j.jcjd.2015.09.083.

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.

Diabetes Obes Metab. 2016 Feb;18(2):159-68. doi: 10.1111/dom.12584. Epub 2016 Jan 8.

Hypoglycaemia: costs, insulins and prevention.

Diabet Med. 2016 Apr;33(4):419-20. doi: 10.1111/dme.13100.

Biosimilars and Novel Insulins.

Am J Ther. 2020 Jan/Feb;27(1):e52-e61. doi: 10.1097/MJT.0000000000001079.

Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.

PLoS One. 2018 Apr 18;13(4):e0195012. doi: 10.1371/journal.pone.0195012. eCollection 2018.

引用本文的文献

An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift.

Biomolecules. 2018 Sep 5;8(3):89. doi: 10.3390/biom8030089.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2017 Feb;19(S1):S42-S58. doi: 10.1089/dia.2017.2505.

Role of Devices in Insulin Delivery.

Diabetes Technol Ther. 2017 Feb;19(2):76-78. doi: 10.1089/dia.2017.0011.

Novel and Emerging Insulin Preparations for Type 2 Diabetes.

Can J Diabetes. 2015 Dec;39 Suppl 5:S160-6. doi: 10.1016/j.jcjd.2015.09.082.

New Medications for the Treatment of Diabetes.

Diabetes Technol Ther. 2017 Feb;19(S1):S128-S140. doi: 10.1089/dia.2017.2512.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2018 Feb;20(S1):S55-S70. doi: 10.1089/dia.2018.2505.

Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.

Can J Diabetes. 2015 Dec;39 Suppl 5:S176-82. doi: 10.1016/j.jcjd.2015.09.083.

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.

Diabetes Obes Metab. 2016 Feb;18(2):159-68. doi: 10.1111/dom.12584. Epub 2016 Jan 8.

Hypoglycaemia: costs, insulins and prevention.

Diabet Med. 2016 Apr;33(4):419-20. doi: 10.1111/dme.13100.

Biosimilars and Novel Insulins.

Am J Ther. 2020 Jan/Feb;27(1):e52-e61. doi: 10.1097/MJT.0000000000001079.

Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.

PLoS One. 2018 Apr 18;13(4):e0195012. doi: 10.1371/journal.pone.0195012. eCollection 2018.

引用本文的文献

An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift.

Biomolecules. 2018 Sep 5;8(3):89. doi: 10.3390/biom8030089.